Indications |
Intravenous Acute heart failure Adult: 2.5-10 mcg/kg, up to 0.5-40 mcg/kg according to patient's heart rate, cardiac output, BP and urine output. Intravenous Cardiac stress test Adult: 5 mcg/kg/min for 8 min using a 1 mg/ml solution, dose is then increased at 5 mcg/kg/min until 20 mcg/kg/min, with each dose being infused for 8 min before the next increase. Monitor ECG and stop infusion if arrhythmias, marked ST segment depression or other adverse effects occur. |
Contraindications |
Hypersensitivity; idiopathic hypertrophic subaortic stenosis (IHSS). |
Warnings / Precautions |
Correct hypovolaemia prior to treatment. Increased risk of rapid ventricular response in patients with atrial fibrillation. Insufficient data to determine the safety and efficacy of dobutamine use after acute MI. Elderly. Neonates. Pregnancy. |
Adverse Reactions |
Increased heart rate and BP, ectopic beats, palpitation. Nausea, headache, chest pain, palpitation, dyspnoea, paraesthesia, leg cramps. Tissue necrosis at site of extravasation. Potentially Fatal: Cardiac arrhythmias, allergy (rare), MI and hypotension. |
Overdose Reactions |
Symptoms may include anorexia, nausea, vomiting, tremor, anxiety, palpitations, headache, shortness of breath, and anginal and nonspecific chest pain. Treatment includes discontinuing drug admin, establishing an airway, ensuring oxygenation and ventilation. Initiate resuscitative measures immediately. Severe ventricular tachyarrhythmias may be treated with propranolol or lidocaine. Hypertension usually responds to dose reduction or therapy discontinuation. |
Drug Interactions |
Increased cardiac output when used with nitroprusside. Increased vasopressor effect of dobutamine when used with bretylium, guanethidine, oxytocic drugs or TCAs. See Below for More dobutamine Drug Interactions |
Mechanism of Actions |
Dobutamine increases contractility and heart rate by stimulating β-adrenergic receptors in the cardiac tissues. Absorption: Inactivated in the GI tract (oral). Metabolism: Converted to 3-O-methyldobutamine. Excretion: Mainly via urine, via faeces (small amounts); 2 min (elimination half-life). |
Storage Conditions |
Intravenous: Store at 15-30°C. |
ATC Classification |
C01CA07 - dobutamine ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of heart failure. |
Storage |
Intravenous: Store at 15-30°C. |
Available As |
|
Dobutamine
Post Review about Dobutamine Click here to cancel reply.
Dobutamine Containing Brands
Dobutamine is used in following diseases
Drug - Drug Interactions of Dobutamine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.